Role of central kisspeptin and RFRP-3 in energy metabolism in the male Wistar rat.
RF-amides
food intake
glucose homeostasis
hypothalamus
luteinising hormone
reproduction
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
07 May 2021
07 May 2021
Historique:
revised:
12
03
2021
received:
20
01
2021
accepted:
24
03
2021
pubmed:
8
5
2021
medline:
8
5
2021
entrez:
7
5
2021
Statut:
aheadofprint
Résumé
Kisspeptin (Kp) and (Arg)(Phe) related peptide 3 (RFRP-3) are two RF-amides acting in the hypothalamus to control reproduction. In the past 10 years, it has become clear that, apart from their role in reproductive physiology, both neuropeptides are also involved in the control of food intake, as well as glucose and energy metabolism. To investigate further the neural mechanisms responsible for these metabolic actions, we assessed the effect of acute i.c.v. administration of Kp or RFRP-3 in ad lib. fed male Wistar rats on feeding behaviour, glucose and energy metabolism, circulating hormones (luteinising hormone, testosterone, insulin and corticosterone) and hypothalamic neuronal activity. Kp increased plasma testosterone levels, had an anorexigenic effect and increased lipid catabolism, as attested by a decreased respiratory exchange ratio (RER). RFRP-3 also increased plasma testosterone levels but did not modify food intake or energy metabolism. Both RF-amides increased endogenous glucose production, yet with no change in plasma glucose levels, suggesting that these peptides provoke not only a release of hepatic glucose, but also a change in glucose utilisation. Finally, plasma insulin and corticosterone levels did not change after the RF-amide treatment. The Kp effects were associated with an increased c-Fos expression in the median preoptic area and a reduction in pro-opiomelanocortin immunostaining in the arcuate nucleus. No effects on neuronal activation were found for RFRP-3. Our results provide further evidence that Kp is not only a very potent hypothalamic activator of reproduction, but also part of the hypothalamic circuit controlling energy metabolism.
Identifiants
pubmed: 33960524
doi: 10.1111/jne.12973
pmc: PMC8365661
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12973Subventions
Organisme : Neurotime Erasmus+
Organisme : Agence Nationale de la Recherche
ID : ANR- 13-BSV1-001
Informations de copyright
© 2021 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
Références
J Comp Neurol. 2016 Jun 15;524(9):1825-38
pubmed: 26518222
J Clin Invest. 2014 Jul;124(7):3075-9
pubmed: 24937427
Front Endocrinol (Lausanne). 2020 Apr 09;11:194
pubmed: 32328034
J Comp Neurol. 2014 Dec 1;522(17):3817-33
pubmed: 24978951
Clin Chim Acta. 2016 Feb 15;454:112-8
pubmed: 26778410
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5813-8
pubmed: 21402951
Lancet Diabetes Endocrinol. 2020 Jun;8(6):524-534
pubmed: 32445739
Endocrinology. 2005 Sep;146(9):3917-25
pubmed: 15932928
Metabolism. 2019 Sep;98:84-94
pubmed: 31226351
Am J Physiol Regul Integr Comp Physiol. 2001 Aug;281(2):R444-51
pubmed: 11448846
J Neurosci. 2010 Jul 28;30(30):10205-19
pubmed: 20668204
Biochem Biophys Res Commun. 2000 Aug 28;275(2):661-7
pubmed: 10964719
J Neuroendocrinol. 2019 Apr;31(4):e12710
pubmed: 30887598
Nat Commun. 2019 Jan 18;10(1):311
pubmed: 30659173
J Neuroendocrinol. 2004 Oct;16(10):850-8
pubmed: 15500545
J Clin Endocrinol Metab. 2011 Dec;96(12):E1963-72
pubmed: 21976724
Sci Rep. 2016 Nov 02;6:36057
pubmed: 27805048
Curr Biol. 2019 Feb 18;29(4):592-604.e4
pubmed: 30744968
Endocrinology. 2012 Mar;153(3):1352-63
pubmed: 22275511
Peptides. 2019 Feb;112:114-124
pubmed: 30562556
J Neuroendocrinol. 2016 Apr;28(4):
pubmed: 26791158
Mol Endocrinol. 2016 Jun;30(6):630-44
pubmed: 27093227
Metabolism. 2018 Oct;87:87-97
pubmed: 30075164
EMBO J. 2012 Nov 14;31(22):4252-4
pubmed: 23085989
J Neurosci. 2015 Nov 18;35(46):15419-29
pubmed: 26586828
FASEB J. 2020 Jan;34(1):107-121
pubmed: 31914628
Molecules. 2018 Nov 24;23(12):
pubmed: 30477219
J Neurosci. 2019 Apr 24;39(17):3234-3248
pubmed: 30782975
J Neuroendocrinol. 2017 Feb;29(2):
pubmed: 27981646
J Neuroendocrinol. 2021 May 7;33(7):e12973
pubmed: 33960524
Endocrinology. 2017 Oct 1;158(10):3526-3539
pubmed: 28977590
Cell Rep. 2017 Sep 26;20(13):3034-3042
pubmed: 28954222
Endocrinology. 2017 Sep 1;158(9):2873-2883
pubmed: 28475692
Front Endocrinol (Lausanne). 2019 Apr 10;10:183
pubmed: 31024442
J Physiol. 2009 Apr 1;587(Pt 7):1401-11
pubmed: 19204051
J Comp Neurol. 2017 Feb 15;525(3):411-441
pubmed: 27503597
Neuroendocrinology. 2012;95(4):305-16
pubmed: 22286004
Int J Endocrinol. 2014;2014:143763
pubmed: 24812558
Trends Neurosci. 2013 Sep;36(9):504-12
pubmed: 23790727
PLoS One. 2015 Jun 18;10(6):e0130822
pubmed: 26087133
Eur J Neurosci. 2020 Jan;51(1):509-530
pubmed: 30472752
Science. 1997 Oct 3;278(5335):135-8
pubmed: 9311920
Endocrinology. 2006 May;147(5):2183-96
pubmed: 16469808
J Neuroendocrinol. 2009 Aug;21(8):690-7
pubmed: 19500220
J Neuroendocrinol. 2014 Apr;26(4):247-57
pubmed: 24612072
Physiol Rev. 2012 Jul;92(3):1235-316
pubmed: 22811428
Endocrinology. 2013 Dec;154(12):4939-45
pubmed: 24092638
Horm Behav. 2007 Jan;51(1):171-80
pubmed: 17113584
J Endocrinol Invest. 2021 Apr;44(4):819-842
pubmed: 32772323
Front Endocrinol (Lausanne). 2016 Feb 03;7:6
pubmed: 26869993
Ann N Y Acad Sci. 1959 Sep 25;82:420-30
pubmed: 13833973
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2410-5
pubmed: 16467147
J Neuroendocrinol. 2020 May;32(5):e12845
pubmed: 32291844
J Mol Endocrinol. 2016 May;56(4):T157-74
pubmed: 26939593
J Neuroendocrinol. 2018 Jul;30(7):e12597
pubmed: 29624758
Sci Rep. 2016 Nov 25;6:37435
pubmed: 27886210
Endocrinology. 2010 May;151(5):2233-43
pubmed: 20207832
J Clin Invest. 2007 Nov;117(11):3475-88
pubmed: 17885689
Neuroreport. 2011 Mar 30;22(5):253-7
pubmed: 21386700